BiomX Inc. Announces 1-for-19 Reverse Stock Split

Core Viewpoint - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025, to enhance its stock price and maintain compliance with NYSE American listing requirements [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert nineteen current shares into one new share, affecting all stockholders uniformly without altering their percentage ownership interest [3][4]. - The number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640, with adjustments for fractional shares [4]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up to the next whole share [4]. Group 2: Company Background - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting harmful bacteria for chronic diseases with significant unmet needs [5]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [5].